Speaker: Alastair Greystoke

1:05:33

Dr Alastair Greystoke & Dr Tom Newsom-Davis - “Local or Centralised Care”

0:41:24

Dr Alastair Greystoke debates with Dr Tom Newsom-Davis “Lorlatinib – first or last?”

0:00:51

Highlights from BTOG 2021

0:02:08

Managing lung cancer in ILD patients and implementing ctDNA testing in the NHS

0:00:52

Systemic treatment following immunotherapy

0:00:34

CAR T-cell therapy for lung cancer?

0:01:41

Key challenges in lung cancer treatment

0:01:41

Importance of occupational therapy for patients in early clinical trials

0:00:39

Progress in novel NSCLC therapies in the UK

0:01:51

NHS England: a pilot ctDNA study to track patient responses to novel genomic targets

0:02:19

Inequalities in biomarker testing

0:01:04

BTOG 2024 highlights: MARS 2 trial on mesothelioma surgery and TRACERx on lung cancer evolution

0:04:53

Developments in personalized therapies for lung cancer

0:03:34

Strategies to improve biomarker testing in the UK

0:01:02

Combination and monotherapies in NSCLC

0:05:59

Deciphering an NGS report in lung cancer

0:01:50

Future lung cancer drug approvals in the UK

0:05:51

NSCLC biomarker testing in the UK

0:02:08

Lung cancer frailty research

0:06:20

Solid tumor genomic testing in the UK: challenges and solutions

0:01:13

Guiding NSCLC treatment with biomarkers

0:01:07

Checkpoint inhibitors for lung cancer: combating resistance

0:02:12

The impact of selpercatinib in patients with RET fusion-positive NSCLC

0:10:58

Clinical frailty scale: predictor of prognosis for patients